(98 days)
Not Found
No
The device description and performance studies focus on the chemical composition and biological effects of a handling solution, with no mention of AI or ML technologies.
No.
The device is a solution intended for in vitro procedures involving the handling and micromanipulation of gametes and embryos, and is not directly applied to a patient for diagnosis, cure, mitigation, treatment, or prevention of disease.
No
This device is described as a non-viscous, ready-to-use solution providing supporting conditions for human gametes and embryos during in vitro Assisted Reproduction Technology (ART) procedures. Its intended use focuses on handling and manipulation, not on diagnosing a condition or disease.
No
The device description clearly states it is a "non-viscous, ready-to-use solution" composed of various chemical components, indicating it is a liquid medium, not software. The performance studies also focus on chemical and biological properties, not software validation.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states "in vitro procedures involving handling and micromanipulation of gametes and embryos". This clearly indicates the device is used outside of the body for diagnostic or therapeutic purposes related to human reproduction.
- Device Description: The description details a "ready-to-use solution providing supporting conditions for human gametes and embryos during in vitro Assisted Reproduction Technology (ART) procedures". This further reinforces its use in an in vitro setting.
- Performance Studies: The performance studies include tests like "Mouse embryo assay (MEA)" and "Human Sperm Survival Assay (HSSA)". These are tests performed on biological samples (embryos and sperm) outside the body to assess the device's suitability for its intended use in ART procedures.
- Predicate Device: The predicate device, "Quinn's Advantage Medium with HEPES", is also a known IVD used in ART procedures.
While the device itself is a solution used during in vitro procedures, its purpose is to support and facilitate these procedures which are inherently in vitro diagnostic and therapeutic processes related to human reproduction. Therefore, it falls under the definition of an IVD.
N/A
Intended Use / Indications for Use
ORIGIO® Handling™ is intended for in vitro procedures involving handling and micromanipulation of gametes and embryos outside the CO2 incubator.
Indication includes oocyte retrieval including follicle flushing, gamete (oocyte/sperm) and embryo washing, and micromanipulation procedures including Intra Cytoplasmic Sperm Injection (ICSI), assisted hatching and trophectodern biopsy.
Product codes
MQL
Device Description
ORIGIO® Handling™ is a non-viscous, ready-to-use solution providing supporting conditions for human gametes and embryos during in vitro Assisted Reproduction Technology (ART) procedures taking place outside the CO2 incubator. This product can also be used for oocyte retrieval including follicle flushing.
ORIGIO® Handling™ consists of amino acids, glucose, physiological salts, calcium lactate, sodium pyruvate, vitamins, sodium bicarbonate MOPS/HEPES, human serum albumin, and gentamicin sulfate. This product is supplied with phenol red (Cat. No. 8311) or without phenol red (Cat. No. 8310).
ORIGIO® Handling™ is a single-use device that is aseptically filled into sterilized bottles (60 and 125 ml) and has a sterility assurance level (SAL) of 103. The product is stored at 2-8℃, and if not warmed, the product can be used for up to seven days after bottle opening. Prior to use, ORIGIO® Handling™ must be pre-warmed to 37℃, except for sperm washin g procedures where the product is pre-warmed to room temperature before use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
- pH testing per USP
- Osmolality per USP
- Aseptic Processing Validation study per ISO 13408-2:2011
- Sterility testing per USP
- Endotoxin testing per USP
- Mouse embryo assay (MEA): One-cell mouse embryos were exposed to subject devices and cultured at 37°C in an atmosphere containing 5% CO2. The percent of embryos developed to the expanded blastocyst stage within 96 hours were assessed in comparison with the control group.
- Human Sperm Survival Assay (HSSA): One part sperm suspension and five parts medium are mixed and sperm motility assessed using a Computer Assisted Sperm Analyzer (CASA) at time zero (control) and 6 hours after incubation at room temperature. The percentage of motile sperm at 6 hours is compared with the control.
- Biocompatibility studies:
- Cytotoxicity testing per 10993-5:2009
- Local Lymph Node Assay (LLNA) testing per ISO 10993-10:2010
- Vaginal Irritation testing per ISO 10993-10:2010
- Shelf-life studies (real-time) were conducted to ensure that the following product specifications are met at time zero and the end of the shelf-life:
- pH
- Osmolality
- 1-cell MEA - ≥80% developed to the blastocyst stage at 96 hours
- HSSA – Sperm motility ≥80% of control after incubation for 6 hours
- Endotoxin - ≤0.1 EU/ml (LAL)
- Sterility - No microbiological growth
Key Metrics
- pH: 7.3-7.5
- Osmolality: 277-293 mOsm/kg
- 1-cell MEA: ≥80% developed to the blastocyst stage at 96 hours
- HSSA: Sperm motility ≥80% of control after incubation for 6 hours
- Endotoxin: ≤0.1 EU/ml (LAL)
- Sterility: No microbiological growth
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 884.6180 Reproductive media and supplements.
(a)
Identification. Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.).(b)
Classification. Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
March 2, 2018
Origio a/s Tove Kjaer Director, Corporate Regulatory Affairs Knardrupvej 2 2760 Måløv Denmark
Re: K173624
Trade/Device Name: ORIGIO® Handling™ without phenol red (Cat. No. 8310), ORIGIO® Handling™ with phenol red (Cat. No. 8311) Regulation Number: 21 CFR 884.6180 Regulation Name: Reproductive media and supplements Regulatory Class: Class II Product Code: MOL Dated: November 28, 2017 Received: December 4, 2017
Dear Tove Kjaer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For
Charles Viviano -S
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K173624
Device Name ORIGIO® Handling™ (Cat. No. 8310) ORIGIO® Handling™ with phenol red (Cat. No. 8311)
Indications for Use (Describe)
ORIGIO® Handling™ is intended for in vitro procedures involving handling and micromanipulation of gametes and embryos outside the CO2 incubator.
Indication includes oocyte retrieval including follicle flushing, gamete (oocyte/sperm) and embryo washing, and micromanipulation procedures including Intra Cytoplasmic Sperm Injection (ICSI), assisted hatching and trophectodern biopsy.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/1 description: The image shows the word "origio" in a stylized, sans-serif font. The letters are a deep purple color. The "i" in "origio" is stylized with a comma-like shape above the lower part of the letter. The background is plain white.
K173624 - ORIGIO® Handling™
510(k) SUMMARY
| Submitted By: | ORIGIO a/s
Knardrupvej 2
2760 Måløv
Denmark |
|------------------------|----------------------------------------------------------------------------------------------------------------|
| Contact Person: | Tove Kjær
Director Corporate Regulatory Affairs
ORIGIO a/s
Phone: +45 4679 0220
Fax: +45 4679 0300 |
| Date Prepared: | March 1, 2018 |
| Device Identification: | |
| Trade name: | ORIGIO® Handling™ without phenol red (Cat. No. 8310)
ORIGIO® Handling™ with phenol red (Cat. No. 8311) |
| Common name: | Embryo Culture Media |
| Classification name: | Reproductive Media and Supplements (21 CFR 884.6180) |
| Product code: | MQL (Media, Reproductive) |
Regulatory class: =
Predicate Device:
Quinn's Advantage Medium with HEPES (K002836). This predicate device has not been subject to any design related recalls.
Device Description:
ORIGIO® Handling™ is a non-viscous, ready-to-use solution providing supporting conditions for human gametes and embryos during in vitro Assisted Reproduction Technology (ART) procedures taking place outside the CO2 incubator. This product can also be used for oocyte retrieval including follicle flushing.
ORIGIO® Handling™ consists of amino acids, glucose, physiological salts, calcium lactate, sodium pyruvate, vitamins, sodium bicarbonate MOPS/HEPES, human serum albumin, and gentamicin sulfate. This product is supplied with phenol red (Cat. No. 8311) or without phenol red (Cat. No. 8310).
ORIGIO® Handling™ is a single-use device that is aseptically filled into sterilized bottles (60 and 125 ml) and has a sterility assurance level (SAL) of 103. The product is stored at 2-8℃, and if not warmed, the product can be used for up to seven days after bottle opening. Prior
4
Image /page/4/Picture/1 description: The image shows the word "origio" in a stylized font. The letters are purple and have a rounded appearance. The letter "i" is slightly smaller and offset from the other letters.
to use, ORIGIO® Handling™ must be pre-warmed to 37℃, except for sperm washin g procedures where the product is pre-warmed to room temperature before use.
Indication for Use:
ORIGIO® Handling™ is intended for in vitro procedures involving handling and micromanipulation of gametes and embryos outside the CO2 incubator.
Indication includes oocyte retrieval including follicle flushing, gamete (oocyte/sperm) and embryo washing, and micromanipulation procedures including Intra Cytoplasmic Sperm Injection (ICSI), assisted hatching and trophectoderm biopsy.
Comparison of Intended Use and Technological Characteristics of the Subject and Predicate Devices:
| Device/Predicate
| Device(s) | Subject device (K173624) | Predicate device (K002836) |
|---|---|---|
| Indications for | ||
| Use | ORIGIO® Handling™ is intended for in vitro | |
| procedures involving handling and | ||
| micromanipulation of gametes and embryos | ||
| outside the CO2 incubator. | Quinn's Advantage Medium | |
| with HEPES is for in vitro | ||
| procedures involving | ||
| manipulations of gametes and | ||
| embryos not requiring the use | ||
| of a CO2 incubator. | ||
| Indication includes oocyte retrieval including | ||
| follicle flushing, gamete (oocyte/sperm) and | ||
| embryo washing, and micromanipulation | ||
| procedures including Intra Cytoplasmic | ||
| Sperm Injection (ICSI), assisted hatching, | ||
| and trophectoderm biopsy. | ||
| pH | 7.3-7.5 | 7.0-7.4 |
| Osmolality | 277-293 mOsm/kg | 257-273 mOsm/kg |
| Formulation | Comparable | Comparable |
The indications for use for the subject and predicate devices are not identical as the subject device has specific indications for oocyte retrieval, gamete and embryo washing, and micromanipulation procedures including ICSI, assisted hatching, and trophectoderm biopsy, whereas the predicate indication does not include these specific uses. These uses do not represent a new intended use as they fall within the scope of media used for handling and manipulation of gametes and embryos outside of a CO2 incubator.
In regards to device technical characteristics, there are minor differences pH, osmolality and formulations between the subject and predicate devices. These differences do not raise different questions of safety and effectiveness.
Summary of Non-Clinical Performance Testing:
The following studies have been performed to support substantial equivalence to the predicate devices:
- . pH testing per USP
- . Osmolality per USP
- Aseptic Processing Validation study per ISO 13408-2:2011
5
- Sterility testing per USP ●
- Endotoxin testing per USP ●
- . Mouse embryo assay (MEA)
One-cell mouse embryos were exposed to subject devices and cultured at 37°C in an atmosphere containing 5% CO2. The percent of embryos developed to the expanded blastocyst stage within 96 hours were assessed in comparison with the control group.
-
Human Sperm Survival Assay (HSSA) .
One part sperm suspension and five parts medium are mixed and sperm motility assessed using a Computer Assisted Sperm Analyzer (CASA) at time zero (control) and 6 hours after incubation at room temperature. The percentage of motile sperm at 6 hours is compared with the control. -
. Biocompatibility studies, as follows:
-
- Cytotoxicity testing per 10993-5:2009
-
- Local Lymph Node Assay (LLNA) testing per ISO 10993-10:2010
-
- Vaginal Irritation testing per ISO 10993-10:2010
-
-
. Shelf-life studies (real-time) were conducted to ensure that the following product specifications are met at time zero and the end of the XX shelf-life.
-
- pH - See tables above
-
- Osmolality - See tables above
-
- 1-cell MEA - ≥80% developed to the blastocyst stage at 96 hours
-
- HSSA – Sperm motility ≥80% of control after incubation for 6 hours
- ★ Endotoxin - ≤0.1 EU/ml (LAL)
- ★ Sterility - No microbiological growth
-
Conclusion
The subject and predicate devices have the same intended use and comparable technological characteristics. The differences in technological characteristics between subject and predicate devices do not raise different questions of safety and effectiveness. The performance data demonstrate that the subject device is substantially equivalent to the predicate device.